The University of Southampton
University of Southampton Institutional Repository

NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer

NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer
NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer
We hypothesise that the NRF2 transcription factor would act a biomarker of poor prognosis in colorectal cancer. We derived and validated an mRNA based metagene signature of NRF2 signalling and validated it in 1360 patients from 4 different datasets as an independent biomarker of poor prognosis. This is a novel insight into the molecular signalling of colorectal cancer.

Background: NRF2 over activity confers poor prognosis in some cancers but its prognostic role in colorectal cancer (CRC) is unknown. As a transcription factor, we hypothesise a signature of NRF2 regulated genes could act as a prognostic biomarker in CRC and reveal novel biological insights.

Methods: Using known NRF2 regulated genes, differentially expressed in CRC, we defined a signature of NRF2 pathway activity using principal component analysis and Cox proportional hazard models and tested it in four independent mRNA datasets, profiled on three different mRNA platforms.

Results: 36 genes comprised the final NRF2 signature. 1360 patients were included in the validation. High NRF2 was associated with worse disease free survival (DFS) and/or overall survival (OS) in all datasets: (GSE14333 HR=1.55, 95% C.I 1.2–2.004, p = 0.0008; GSE39582 HR=1.24, 95% C.I 1.086–1.416, p = 0.001; GSE87211 HR=1.431, 95% C.I 1.06–1.93, p = 0.056; MRC FOCUS trial HR=1.14, 95% C.I 1.04–1.26, p = 0.008). In multivariate analyses, NRF2 remained significant when adjusted for stage and adjuvant chemotherapy in stage I-III disease, and BRAF V600E mutation and sidedness in stage IV disease. NRF2 activity was particularly enriched in Consensus Molecular Subtype (CMS) 4.

Conclusion: For the first time, NRF2 is shown to be a consistent, robust prognostic biomarker across all stages of colorectal cancer with additional clinical value to current known prognostic biomarkers. High NRF2 signalling in CMS 4 further refines the molecular taxonomy of CRC, a new biological insight, suggesting avenues of further study.
1-10
O'Cathail, Séan M.
56b42a11-1955-45f0-a790-7e3512dfb941
Wu, Chieh-Hsi
ace630c6-2095-4ade-b657-241692f6b4d3
Lewis, Annabelle
028f9aa4-a580-4366-ad83-577ebf7b9fc6
Holmes, Chris
a4d53eee-2215-4c7c-a680-ec13202a629f
Hawkins, Maria A
fe46c6fb-a77c-4308-8861-48b34a65c2f3
Maughan, Tim
9f5b1ca4-9ed7-4100-bf04-c4026e4b5395
O'Cathail, Séan M.
56b42a11-1955-45f0-a790-7e3512dfb941
Wu, Chieh-Hsi
ace630c6-2095-4ade-b657-241692f6b4d3
Lewis, Annabelle
028f9aa4-a580-4366-ad83-577ebf7b9fc6
Holmes, Chris
a4d53eee-2215-4c7c-a680-ec13202a629f
Hawkins, Maria A
fe46c6fb-a77c-4308-8861-48b34a65c2f3
Maughan, Tim
9f5b1ca4-9ed7-4100-bf04-c4026e4b5395

O'Cathail, Séan M., Wu, Chieh-Hsi, Lewis, Annabelle, Holmes, Chris, Hawkins, Maria A and Maughan, Tim (2020) NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer Genetics, 248-249, 1-10. (doi:10.1016/j.cancergen.2020.08.006).

Record type: Article

Abstract

We hypothesise that the NRF2 transcription factor would act a biomarker of poor prognosis in colorectal cancer. We derived and validated an mRNA based metagene signature of NRF2 signalling and validated it in 1360 patients from 4 different datasets as an independent biomarker of poor prognosis. This is a novel insight into the molecular signalling of colorectal cancer.

Background: NRF2 over activity confers poor prognosis in some cancers but its prognostic role in colorectal cancer (CRC) is unknown. As a transcription factor, we hypothesise a signature of NRF2 regulated genes could act as a prognostic biomarker in CRC and reveal novel biological insights.

Methods: Using known NRF2 regulated genes, differentially expressed in CRC, we defined a signature of NRF2 pathway activity using principal component analysis and Cox proportional hazard models and tested it in four independent mRNA datasets, profiled on three different mRNA platforms.

Results: 36 genes comprised the final NRF2 signature. 1360 patients were included in the validation. High NRF2 was associated with worse disease free survival (DFS) and/or overall survival (OS) in all datasets: (GSE14333 HR=1.55, 95% C.I 1.2–2.004, p = 0.0008; GSE39582 HR=1.24, 95% C.I 1.086–1.416, p = 0.001; GSE87211 HR=1.431, 95% C.I 1.06–1.93, p = 0.056; MRC FOCUS trial HR=1.14, 95% C.I 1.04–1.26, p = 0.008). In multivariate analyses, NRF2 remained significant when adjusted for stage and adjuvant chemotherapy in stage I-III disease, and BRAF V600E mutation and sidedness in stage IV disease. NRF2 activity was particularly enriched in Consensus Molecular Subtype (CMS) 4.

Conclusion: For the first time, NRF2 is shown to be a consistent, robust prognostic biomarker across all stages of colorectal cancer with additional clinical value to current known prognostic biomarkers. High NRF2 signalling in CMS 4 further refines the molecular taxonomy of CRC, a new biological insight, suggesting avenues of further study.

Text
1-s2.0-S2210776220302623-main - Version of Record
Download (1MB)

More information

Accepted/In Press date: 17 August 2020
e-pub ahead of print date: 21 August 2020
Published date: October 2020

Identifiers

Local EPrints ID: 453347
URI: http://eprints.soton.ac.uk/id/eprint/453347
PURE UUID: 9d9fab27-10cd-4e4c-98a3-9a4e4a44b87e
ORCID for Chieh-Hsi Wu: ORCID iD orcid.org/0000-0001-9386-725X

Catalogue record

Date deposited: 13 Jan 2022 17:52
Last modified: 17 Mar 2024 04:00

Export record

Altmetrics

Contributors

Author: Séan M. O'Cathail
Author: Chieh-Hsi Wu ORCID iD
Author: Annabelle Lewis
Author: Chris Holmes
Author: Maria A Hawkins
Author: Tim Maughan

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×